CD30: receptor, marker, target

References

• Stein H, Gerdes J, Kirchner H, Schaadt M, Diehl V. Hodgkin and Sternberg-Reed cell antigen(s) detected by an antiserum to a cell line (L428) derived from Hodgkin disease. Int J Cancer. 1981;28(4):425–429.
   Web of Science ®Google Scholar
• Dürkop H, Latza U, Hummel M, Eitelbach F, Seed B, Stein H. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin’s disease. Cell. 1992; 68(3):421–427.
   PubMed Web of Science ®Google Scholar
• Smith CA, Gruss HJ, Davis T, et al. CD30 antigen, a marker for Hodgkin’s lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell. 1993;73(7):1349–1360.
   PubMed Web of Science ®Google Scholar
• Gedrich RW, Gilfillan MC, Duckett CS, Van Dongen JL, Thompson CB. CD30 contains two binding sites with different specificities for members of the tumor necrosis factor receptor-associated factor family of signal transducing proteins. J Biol Chem. 1996;271(22):12852–12858.
   Web of Science ®Google Scholar
• Ellis TM, Simms PE, Slivnick DJ, Jäck HM, Fisher RI. CD30 is a signal-transducing molecule that defines a subset of human activated CD45RO+ T cells. J Immunol. 1993;151(5):2380–2389.
   Web of Science ®Google Scholar
• Gilfillan MC, Noel PJ, Podack ER, Reiner SL, Thompson CB. Expression of the costimulatory receptor CD30 is regulated by both CD28 and cytokines. J Immunol. 1998;160(5):2180–2187.
   PubMed Web of Science ®Google Scholar
• Stein H, Gerdes J, Schwab U, et al. Identification of Hodgkin and Sternberg-Reed cells as a unique cell type derived from a newly-detected small-cell population. Int J Cancer. 1982;30(4):445–459.
   Web of Science ®Google Scholar
• Cerutti A, Schaffer A, Goodwin R, et al. Engagement of CD153 (CD30L) by CD30+ T cells inhibits class switch DNA recombination and antibody production in Human IgD+ IgM+ B cells. J Immunol. 2000;165(2):786–794.
   Web of Science ®Google Scholar
• Kennedy MK, Willis CR, Armitage RJ. Deciphering CD30 ligand biology and its role in humoral immunity. Immunology. 2006;118(2):143–152.
   PubMed Web of Science ®Google Scholar
• Falini B, Pileri S, Pizzolo G, et al. CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood. 1995;85(1):1–14.
   PubMed Web of Science ®Google Scholar
• Pizzolo G, Vinante F, Chilosi M, et al. Serum levels of soluble CD30 molecule (Ki-1 antigen) in Hodgkin’s disease: relationship with disease activity and clinical stage. Br J Haematol. 1990;75(2):282–284.
   Web of Science ®Google Scholar
• Nadali G, Vinante F, Stein H, et al. Serum levels of the soluble form of CD30 molecule as a tumor marker in CD30+ anaplastic large-cell lymphoma. J Clin Oncol. 1995;13(6):1355–1360.
   Web of Science ®Google Scholar
• Caligaris-Cappio F, Bertero MT, Converso M, et al. Circulating levels of soluble CD30, a marker of cells producing Th2-type cytokines, are increased in patients with systemic lupus erythematosus and correlate with disease activity. Clin Exp Rheumatol. 1995;13(3):339–343.
   Web of Science ®Google Scholar
• Latza U, Foss HD, Dürkop H, et al. CD30 antigen in embryonal carcinoma and embryogenesis and release of the soluble molecule. AmJ Pathol. 1995;146(2):463–471.
   PubMed Web of Science ®Google Scholar
• Amakawa R, Hakem A, Kundig TM, et al. Impaired negative selection of T cells in Hodgkin’s disease antigen CD30-deficient mice. Cell. 1996;84(4):551–562.
   Web of Science ®Google Scholar
• Kishimoto H, Sprent J. Several different cell surface molecules control negative selection of medullary thymocytes. J Exp Med. 1999;190(1):65–73.
   Web of Science ®Google Scholar
• Flórido M, Borges M, Yagita H, Appelberg R. Contribution of CD30/CD153 but not of CD27/CD70, CD134/OX40L, or CD137/4-1BBL to the optimal induction of protective immunity to Mycobacterium avium. J Leukoc Biol. 2004;76(5):1039–1046.
   Web of Science ®Google Scholar
• Kurts C, Carbone FR, Krummel MF, Koch KM, Miller JF, Heath WR. Correction: signalling through CD30 protects against autoimmune diabetes mediated by CD8 T cells. Nature. 2000;407(6802):413.
   Web of Science ®Google Scholar
• Gaspal FM, Kim MY, McConnell FM, Raykundalia C, Bekiaris V, Lane PJ. Mice deficient in OX40 and CD30 signals lack memory antibody responses because of deficient CD4 T cell memory. J Immunol. 2005;174(7):3891–3896.
   Web of Science ®Google Scholar
• Hoffmann A, Baltimore D. Circuitry of nuclear factor κB signaling. Immunol Rev. 2006;210:171–186.
   PubMed Web of Science ®Google Scholar
• Kocab AJ, Duckett CS. Inhibitor of apoptosis proteins as intracellular signaling intermediates. FEBS J. 2016;283(2):221–231.
   Web of Science ®Google Scholar
• Aizawa S, Nakano H, Ishida T, et al. Tumor necrosis factor receptor associated factor (TRAF)5 and TRAF2 are involved in CD30-mediated NFKappaB activation. J Biol Chem. 1997;272(4):2042–2045.
   PubMed Web of Science ®Google Scholar
• Buchan SL, Al-Shamkhani A. Distinct motifs in the intracellular domain of human CD30 differentially activate canonical and alternative transcription factor NF-κB signaling. PLOS One. 2012;7(9):e45244.
   Web of Science ®Google Scholar
• Wendtner CM, Schmitt B, Gruss HJ, et al. CD30 ligand signal transduction involves activation of a tyrosine kinase and of mitogen-activated protein kinase in a Hodgkin’s lymphoma cell line. Cancer Res. 1995;55(18):4157–4161.
   Web of Science ®Google Scholar
• Wright CW, Duckett CS. The aryl hydrocarbon nuclear translocator alters CD30-mediated NF-κB-dependent transcription. Science. 2009; 323(5911):251–255.
   Web of Science ®Google Scholar
• Thakar NY, Ovchinnikov DA, Hastie ML, Kobe B, Gorman JJ, Wolvetang EJ. TRAF2 recruitment via T61 in CD30 drives NF-κB activation and enhances hESC survival and proliferation. Mol Biol Cell. 2015;26(5):993–1006.
   Web of Science ®Google Scholar
• Schaadt M, Diehl V, Stein H, Fonatsch C, Kirchner H. Two neoplastic cell lines with unique features derived from Hodgkin’s disease. Int J Cancer. 1980;26(6):723–731.
   Web of Science ®Google Scholar
• Schwab U, Stein H, Gerdes J, et al. Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin’s disease and a subset of normal lymphoid cells. Nature. 1982;299(5878):65–67.
   PubMed Web of Science ®Google Scholar
• Schwarting R, Gerdes J, Dürkop H, Falini B, Pileri S, Stein H. Ber-H2: a new anti-Ki-1 (CD30) monoclonal antibody directed at a formol-resistant epitope. Blood. 1989;74(5):1678–1689.
   PubMed Web of Science ®Google Scholar
• Küppers R, Rajewsky K, Zhao M, et al. Hodgkin disease: Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development. Proc Natl Acad Sci U S A. 1994;91(23):10962–10966.
   PubMed Web of Science ®Google Scholar
• Kanzler H, Küppers R, Hansmann ML, Rajewsky K. Hodgkin and Reed-Sternberg cells in Hodgkin’s disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. J Exp Med. 1996;814(4):1495–1505.
   Google Scholar
• Vockerodt M, Soares M, Kanzler H, et al. Detection of clonal Hodgkin and Reed-Sterberg cells with identical somatically mutated and rearranged VH. Blood. 1998;92(8):2899–2907.
   Web of Science ®Google Scholar
• Leroy X, Augusto D, Leteurtre E, Gosselin B. CD30 and CD117 (c-kit) used in combination are useful for distinguishing embryonal carcinoma from seminoma. J Histochem Cytochem. 2002;50(2):283–285.
   PubMed Web of Science ®Google Scholar
• Dürkop H, Foss HD, Eitelbach F, et al. Expression of CD30 antigen on non-lymphoid tissues and cells. J Pathol. 2000;190(5):613–618.
   PubMed Web of Science ®Google Scholar
• NCCN [homepage on the Internet]. NCCN Guidelines Testicular Cancer version 1.2016. Available from: www.nccn.org. Accessed March 24, 2016.
   Google Scholar
• Mechtersheimer G, Möller P. Expression of Ki-1 antigen (CD30) in mesenchymal tumors. Cancer. 1990;66(8):1732–1737.
   PubMed Web of Science ®Google Scholar
• Mariño-Enríquez A, Wang WL, Roy A, et al. Epithelioid inflammatory myofibroblastic sarcoma: an aggressive intra-abdominal variant of inflammatory myofibroblastic tumor with nuclear membrane or perinuclear ALK. Am J Surg Pathol. 2011;35(1):135–144.
   PubMed Web of Science ®Google Scholar
• Stein H, Marafioti T, Foss HD, et al. Downregulation of BOB.1 and Oct2 in classical Hodgkin disease but not in lymphocyte predominant Hodgkin disease correlates with immunoglobulin transcription. Blood. 2001;97(2):496–501.
   Web of Science ®Google Scholar
• Küpper R. The biology of Hodgkin’s lymphoma. Nat Rev Cancer. 2009;9(1):15–27.
   Web of Science ®Google Scholar
• Scheeren FA, Diehl SA, Smit LA, et al. IL-21 is expressed in Hodgkin lymphoma and activates STAT5; evidence that activated STAT5 is required for Hodgkin lymphomagenesis. Blood. 2008; 111(9):4706–4715.
   Web of Science ®Google Scholar
• Mir SS, Richter BWM, Duckett CS. Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cells. Blood. 2000;96(13):4307–4312.
   PubMed Web of Science ®Google Scholar
• Hirsch B, Hummel M, Bentink S, et al. CD30-induced signaling is absent in Hodgkin’s cells but present in anaplastic large cell lymphoma cells. Am J Pathol. 2008;172(2):510–520.
   Web of Science ®Google Scholar
• Wright CW, Rumble JM, Duckett CS. CD30 activates both the canonical and alternative NF-kB pathways in anaplastic large cell lymphoma cells. J Biol Chem. 2007;282(14):110252–110262.
   Web of Science ®Google Scholar
• Bargou RC, Leng C, Krappmann D, et al. High-level nuclear NF-kB and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells. Blood. 1996;87(10):4340–4347.
   Web of Science ®Google Scholar
• Joos S, Küpper M, Ohl S, et al. Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30+ Hodgkin cells. Cancer Res. 2000;60(3):549–552.
   PubMed Web of Science ®Google Scholar
• Barth TFE, Martin-Subero JI, Joos S, et al. Gains of 2p involving the REL locus correlate with nuclear c-Rel protein accumulation in neoplastic cells of classical Hodgkin lymphoma. Blood. 2003; 101(9):3681–3686.
   PubMed Web of Science ®Google Scholar
• Krappmann D, Emmerich F, Kordes U, Scharschmidt E, Dörken B, Scheidereit C. Molecular mechanisms of constitutive NF-κB/Rel activation in Hodgkin/Reed-Sternberg cells. Oncogene. 1999;18(4):943–953.
   PubMed Web of Science ®Google Scholar
• Jungnickel B. Clonal deleterious mutations in the IκBα gene in the malignant cells in Hodgkin’s disease. J Exp Med. 2000;191(2):395–401.
   PubMed Web of Science ®Google Scholar
• Hinz M, Lemke P, Anagnostopoulos I, et al. Nuclear factor κB-dependent gene expression profiling of Hodgkin’s disease tumor cells, pathogenetic significance, and link to constitutive signal transducer and activator of transcription 5a activity. J Exp Med. 2002;196(5):605–617.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Geneva: WHO Press; 2008.
   Google Scholar
• Stein H, Foss HD, Dürkop H, et al. CD30+ anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood. 2000;96(12):3681–3695.
   PubMed Web of Science ®Google Scholar
• Atsaves V, Lekakis L, Drakos E, et al. The oncogenic JUNB/CD30 axis contributes to cell cycle deregulation in ALK+ anaplastic large cell lymphoma. Br J Haematol. 2014;167(4):514–523.
   Web of Science ®Google Scholar
• Isaacson PG. Enteropathy-associated T-cell lymphoma and other primary intestinal T-cell lymphomas. In: Jaffe ES, Harris NL, Vardiman JW, Campo E, Arber DA, editors. Hematopathology. Missouri: Elsevier Saunders; 2011:580–587.
   Google Scholar
• Sabattini E, Pizzi M, Tabanelli V, et al. CD30 expression in peripheral T-cell lymphomas. Haematologica. 2013;98(8):e81–e82.
   PubMed Web of Science ®Google Scholar
• Harris NL. Shades of gray between large B-cell lymphomas and Hodgkin lymphomas: differential diagnosis and biological implications. Mod Pathol. 2013;26(Suppl 1):S57–S70.
   Google Scholar
• Yao J, Gottesman SRS, Ayalew G, Braverman AS, Axiotis CA. Loss of Foxp3 is associated with CD30 expression in the anaplastic large cell subtype of ATLL in US Caribbean patients. Am J Surg Pathol. 2013;37(9):1407–1412.
   Web of Science ®Google Scholar
• Ansell SM, Horwitz SM, Engert A, et al. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin’s lymphoma and anaplastic large cell lymphoma. J Clin Oncol. 2007;25(19):2764–2769.
   PubMed Web of Science ®Google Scholar
• Bartlett NL, Younes A, Carabasi MH, et al. A phase I multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematological malignancies. Blood. 2008;111(4):1848–1854.
   PubMed Web of Science ®Google Scholar
• Younes A, Gopal AK, Smith SC, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol. 2012;30(18):2183–2189.
   PubMed Web of Science ®Google Scholar
• Francisco JA, Cerveny CG, Meyer DL, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003;102(4):1458–1465.
   PubMed Web of Science ®Google Scholar
• Moskowitz CH, Nademanee A, Masszi T, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;385(9980):1853–1862.
   PubMed Web of Science ®Google Scholar
• Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30(18):2190–2196.
   PubMed Web of Science ®Google Scholar